Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct;65(10):1331-9.
doi: 10.1016/j.addr.2012.07.012. Epub 2012 Aug 17.

Fatty acids as therapeutic auxiliaries for oral and parenteral formulations

Michael J Hackett  1 , Jennica L Zaro, Wei-Chiang Shen, Patrick C Guley, Moo J Cho
Affiliations
Review

Fatty acids as therapeutic auxiliaries for oral and parenteral formulations

Michael J Hackett et al. Adv Drug Deliv Rev. 2013 Oct.

Abstract

Many drugs have decreased therapeutic activity due to issues with absorption, distribution, metabolism and excretion. The co-formulation or covalent attachment of drugs with fatty acids has demonstrated some capacity to overcome these issues by improving intestinal permeability, slowing clearance and binding serum proteins for selective tissue uptake and metabolism. For orally administered drugs, albeit at low level of availability, the presence of fatty acids and triglycerides in the intestinal lumen may promote intestinal uptake of small hydrophilic molecules. Small lipophilic drugs or acylated hydrophilic drugs also show increased lymphatic uptake and enhanced passive diffusional uptake. Fatty acid conjugation of small and large proteins or peptides has exhibited protracted plasma half-lives, site-specific delivery and sustained release upon parenteral administration. These improvements are most likely due to associations with lipid-binding serum proteins, namely albumin, LDL and HDL. These molecular interactions, although not fully characterized, could provide the ability of using the endogenous carrier systems for improving therapeutic outcomes.

Keywords: Albumin; Drug absorption; Drug delivery; Drug formulation; Endogenous drug carriers; Fatty acids; Lipid prodrugs; Protein binding; Reversible lipidization; Triglycerides.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A schematic presentation of the hydrophobic and electrostatic interactions involved in fatty acid-albumin binding (A). The addition of a drug, or surrogate such as fluoresceinamine (blue), may utilize only the hydrophobic interaction (B) or both hydrophobic and electrostatic (red) interactions (C) depending on the modification chemistry.
Figure 2
Figure 2
Artwork depicting the LDL particle. The outer shell contains mostly triglyceride and free cholesterol while the internal core contains mostly cholesteryl ester with some triglyceride. The particle is held together by Apo-B100 which wraps around the particle equatorially. SM, sphingomyelin; PC, phosphatidylcholine; TG, triglyceride; CE, cholesteryl ester; UC, unesterified cholesterol. [Reprinted from, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1488, Tiia Hevonoja, Markku O Pentikäinen, Marja T Hyvönen, Petri T Kovanen, Mika Ala-Korpela, Structure of low density lipoprotein (LDL) particles: Basis for understanding molecular changes in modified LDL, 189–210, Copyright (2000), with permission from Elsevier]
Figure 3
Figure 3
The serum pharmacokinetics of a cholesterol derivative of 32P-labeled siRNA and various 125I-labeled serum components that are known to bind cholesterol. Note that the relatively weak binding of the cholesterol-esterified siRNA to the serum components resulted in a significantly different profile compared to the carriers alone. [Reprinted by permission from Macmillan Publishers Ltd: Nature Biotechnology [82], copyright (2007)]
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Maher S, Leonard TW, Jacobsen J, Brayden DJ. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 2009;61:1427–1449. - PubMed
    1. Mansbach CM, Siddiqi SA. The biogenesis of chylomicrons. Annu. Rev. Physiol. 2010;72:315–333. - PMC - PubMed
    1. Thwaites DT, Anderson CMH. H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp. Physiol. 2007;92:603–619. - PMC - PubMed
    1. Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 1998;284:362–369. - PubMed
    1. Soboll S, Gründel S, Schwabe U, Scholz R. Influence of fatty acids on energy metabolism 2 Kinetics of changes in metabolic rates and changes in subcellular adenine nucleotide contents and pH gradients following addition of octanoate and oleate in perfused rat liver. Eur. J. Biochem. 1984;141:231–236. - PubMed

MeSH terms